FDA approves Atrovent® HFA for treatment of COPD bronchospasms

   blogdigger

Boehringer Ingelheim Pharmaceuticals, Inc announced today that the US Food and Drug Administration has approved new Atrovent® HFA (ipratropium bromide HFA) Inhalation Aerosol indicated as a bronchodilator for maintenance treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), including chronic bronchitis and emphysema... click link for more info.

- link to FDA approves Atrovent® HFA for treatment of COPD bronchospasms -
Last update: 01/25/2005

Recommended Reading

Britain's Franchising Industry: 1991 (Industry Reports)	Negotiating an International Master Franchise Agreement (International Business Negotiating Guides)	Breaking away from franchises and rate cases: A perspective on the evolution of state telecommunications policy (NRRI)	The Franchise Affair (A BBC Audio Colletion)
The Franchise Affair (A BBC Audio Colletion)	1991 Directory of Franchising Organizations (Directory of Franchising Organizations)	The 1995 Franchise Annual: "The Original" Franchise Handbook and Directory (Franchise Annual Directory: The Original Franchise Directory & Handbook)	The Delaware corporate franchise tax